Menu Search
Equities

Moderna Inc

MRNA:NSQ

Moderna Inc

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (USD)68.04
  • Today's Change-1.82 / -2.61%
  • Shares traded5.07m
  • 1 Year change-36.26%
  • Beta1.6845
Data delayed at least 15 minutes, as of Sep 19 2024 20:59 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in USDIncome statement in USDView more

Year on year Moderna Inc's revenues fell -64.45% from 19.26bn to 6.85bn. This along with an increase in selling, general and administrative costs has contributed to a reduction in net income from a gain of 8.36bn to a loss of 4.71bn.
Gross margin65.60%
Net profit margin-116.18%
Operating margin-91.78%
Return on assets-31.24%
Return on equity-40.94%
Return on investment-36.58%
More ▼

Cash flow in USDView more

In 2023, cash reserves at Moderna Inc fell by 289.00m. However, Cash Flow from Investing totalled 4.21bn, indicating this company earned more from the sale of existing assets than it spent on the purchase of new assets. In addition the company used 3.12bn for operations while cash used for financing totalled 1.38bn.
Cash flow per share-13.96
Price/Cash flow per share--
Book value per share30.50
Tangible book value per share30.26
More ▼

Balance sheet in USDView more

Moderna Inc uses little debt in its capital structure as supported by a debt to capital ratio of 4.69%.
Current ratio4.09
Quick ratio3.92
Total debt/total equity0.0492
Total debt/total capital0.0469
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.